

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CHINA MERCHANTS CHINA DIRECT INVESTMENTS LIMITED**

### **招商局中國基金有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code : 133)**

## **INVESTMENT IN IMMVIRA**

China Merchants China Direct Investments Limited (the “**Company**”) announces that Star Group Limited (“**Star Group**”), a wholly-owned subsidiary of the Company, entered into a preferred shares subscription agreement dated 30 September 2022 in relation to Immvira Bioscience Inc. (“**Immvira**”), pursuant to which Star Group agreed to contribute US\$8 million in order to subscribe for the preferred shares issued by Immvira. Upon completion of the transaction, Star Group will own approximately 1.6% in the total issued share capital of Immvira by way of the subscription for the preferred shares.

### **Information on Immvira**

Immvira was incorporated in May 2018. It is principally engaged in clinical research and the development of vector technologies as potential cancer therapeutics. Leveraging intrinsic mechanism of action and tumor microenvironment modification, Immvira focuses on developing a new generation of novel anti-cancer drug vectors, including replicating and non-replicating herpes simplex virus vector, drug delivery exosome and tumor vaccine.

### **Reasons for and Benefits of Investing in Immvira**

The Company considers that genetically modified oncolytic viruses could potentially become a promising anti-cancer therapy. The Company expects that as the proportion of biopharmaceuticals in drug sales is steadily increasing in China, biopharmaceutical companies will have better development opportunities in the future.

The Company believes that the investment in Immvira can further optimize the Company’s investment portfolio and can enable the Company to further increase its stake in biopharmaceutical projects.

For and on behalf of  
CHINA MERCHANTS CHINA DIRECT  
INVESTMENTS LIMITED  
**WANG Xiaoding**  
*Director*

Hong Kong, 30 September 2022

*As at the date hereof, the Executive Directors of the Company are Mr. WANG Xiaoding and Ms. KAN Ka Yee, Elizabeth; the Non-executive Directors are Mr. ZHOU Xing, Mr. ZHANG Rizhong, Mr. KE Shifeng and Mr. TSE Yue Kit; and the Independent Non-executive Directors are Mr. LIU Baojie, Mr. TSANG Wah Kwong, Dr. LI Fang, Dr. GONG Shaolin and Mr. Michael Charles VITERI.*